The Omnipod® 5 Knowledge Hub
Tools to help Australian healthcare professionals and their patients get started with Omnipod 5
Help your patients get the most from their Omnipod 5 Automated Insulin Delivery (AID) system with these downloadable resources, guides, videos, and more.
Guides: Omnipod 5 with Dexcom G6 and Dexcom G7 and FreeStyle Libre 2 Plus sensors*
- Omnipod 5 Technical User Guide (view guide)
- Omnipod 5 User Guide (view guide)
- Omnipod 5 Caregiver Guide (view guide)
- Omnipod 5 & Glooko® Key Information (view guide)
Getting started on Omnipod 5: Guide
Thank you for choosing to prescribe the Omnipod 5 Automated Insulin Delivery system, integrated with Dexcom G6, Dexcom G7, and FreeStyle Libre 2 Plus.
For more information to support patient start-up, see Omnipod 5 training prep for HCPs.
If you require a hard copy of the English Omnipod 5 User Guide or Omnipod 5 Technical User Guide, call 1800 954 074† or +61 2 7208 4352. We'll be happy to help you.
Getting started on the Omnipod 5 Automated Insulin Delivery System Frequently Asked Questions
We have heard from many people in the community regarding their interest in the Omnipod 5 system. Here are answers to some of the community’s most frequently asked questions.
Getting started on Omnipod 5: Videos
These videos tutorials help you and your patients gain a better understanding of the information included in the Omnipod® System training. Share with your patients to help them prepare for their training.
Omnipod 5: The Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ Technology automatically increases, decreases, or pauses insulin delivery, every five minutes, to your personal needs and helps to protect against highs and lows.1,2,‡ Watch this video to learn more.
Initialisation: Learn how SmartAdjust™ works and tips for initialisation with your patients.
Optimisation: Once your patient has successfully started using the system, learn how to optimise it for best results.
Additional Resources
Omnipod® 5 Automated Insulin Delivery System
Meet the next generation Omnipod 5 Automated Insulin Delivery System. Read more.
SmartAdjust™ Technology
SmartAdjust™ Technology automatically increases, decreases, or pauses insulin delivery, every five minutes, to patients’ personal needs which may help to correct highs and protect against lows.1,2 Read more.
Safety and Glycaemic Outcomes
Safety and glycaemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: A single-arm multicenter clinical trial. Read more.
Multicenter Trial of a Tubeless System
Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycaemic targets in paediatric and adult participants with type 1 diabetes. Read more.
Omnipod® 5 Webinars
Join our virtual webinars to get a comprehensive overview of Omnipod® 5 and gain insight on best practices from key opinion leaders. Sign up.
*An appropriate sensor is required for Automated Mode. Boluses for meals and corrections are still necessary. Sensors are sold separately and require a separate prescription. Sensors must be used with compatible apps on a supported smartphone.
†Your call may be recorded for quality monitoring, and training purposes.
‡As with all hybrid closed loop (HCL) systems, you still need to bolus for meals. With Omnipod 5, this is done with the Omnipod 5 Controller.
§The Simulator app is for informational and educational purposes only, hence, the functions are limited in scope and cannot fully depict the Omnipod System’s capabilities. All data is for simulation purposes only and should not be used for therapy decisions. The Simulator app does not control the Omnipod 5 System, does not deliver insulin, and cannot be used for treatment.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.89% vs. 1.32%, P<0.0001; 2.21% vs. 1.78, P=0.8153, respectively.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.43% vs. 2.46%, P=0.0204. Study funded by Insulet.